About this visual
A visual overview of the temporary Medicare GLP-1 Bridge, eligibility pathways, covered medicines, and the $50 monthly copay.
Sources & further reading
Further reading: Current CMS Medicare GLP-1 Bridge program information ↗
Further reading: CMS guidance for providers ↗
This infographic reflects a prelaunch program snapshot. CMS has since published operational updates; rely on its current page for eligibility, products, and process.




Important details on the new CMS GLP-1 Bridge Program for Medicare coverage of obesity medications.
CMS is launching the GLP-1 Bridge Program on July 1, 2026, with coverage available through December 31, 2027 for eligible Medicare beneficiaries.
This program may allow qualifying patients to access certain obesity GLP-1 medications for $50 per monthly supply.
To qualify, patients must be enrolled in either:
• A standalone Medicare Part D prescription drug plan, or
• A Medicare Advantage plan that includes Part D
The medication must be prescribed for reduction of excess body weight and maintenance of weight reduction, along with ongoing lifestyle modification including nutrition and physical activity.
Clinical eligibility includes one of the following:
• BMI ≥ 35
• BMI ≥ 30 plus HFpEF, uncontrolled hypertension, or CKD stage 3a or above
• BMI ≥ 27 plus prediabetes, previous MI, previous stroke, or symptomatic peripheral artery disease
Covered medications currently include:
• Wegovy (injections and tablets)
• Foundayo
• Zepbound KwikPen
One of the most important details: eligibility is based on the patient’s BMI at the time GLP-1 therapy was initiated, not necessarily their BMI at the time of approval. That matters for patients who have already lost weight with treatment.
This is an important step toward providing coverage for cardiometabolic medications that can have profound health benefits beyond weight loss alone.
There is still more work to do, but this is a meaningful step in the right direction for obesity medicine coverage.
I put together this infographic as a quick reference guide.
#ObesityMedicine #GLP1 #Medicare #MedicarePartD #CardiometabolicHealth